BACKGROUND: Continuous EEG monitoring (cEEG) of critically ill patients is frequently utilized to detect non-convulsive seizures (NCS) and status epilepticus (NCSE). The indications for cEEG, as well as when and how to treat NCS, remain unclear. We aimed to describe the current practice of cEEG in critically ill patients to define areas of uncertainty that could aid in designing future research. METHODS: We conducted an international survey of neurologists focused on cEEG utilization and NCS management. RESULTS: Three-hundred and thirty physicians completed the survey. 83% use cEEG at least once per month and 86% manage NCS at least five times per year. The use of cEEG in patients with altered mental status was common (69%), with higher use if the patient had a prior convulsion (89%) or abnormal eye movements (85%). Most respondents would continue cEEG for 24 h. If NCS or NCSE is identified, the most common anticonvulsants administered were phenytoin/fosphenytoin, lorazepam, or levetiracetam, with slightly more use of levetiracetam for NCS than NCSE. CONCLUSIONS: Continuous EEG monitoring (cEEG) is commonly employed in critically ill patients to detect NCS and NCSE. However, there is substantial variability in current practice related to cEEG indications and duration and to management of NCS and NCSE. The fact that such variability exists in the management of this common clinical problem suggests that further prospective study is needed. Multiple points of uncertainty are identified that require investigation.
BACKGROUND: Continuous EEG monitoring (cEEG) of critically illpatients is frequently utilized to detect non-convulsive seizures (NCS) and status epilepticus (NCSE). The indications for cEEG, as well as when and how to treat NCS, remain unclear. We aimed to describe the current practice of cEEG in critically illpatients to define areas of uncertainty that could aid in designing future research. METHODS: We conducted an international survey of neurologists focused on cEEG utilization and NCS management. RESULTS: Three-hundred and thirty physicians completed the survey. 83% use cEEG at least once per month and 86% manage NCS at least five times per year. The use of cEEG in patients with altered mental status was common (69%), with higher use if the patient had a prior convulsion (89%) or abnormal eye movements (85%). Most respondents would continue cEEG for 24 h. If NCS or NCSE is identified, the most common anticonvulsants administered were phenytoin/fosphenytoin, lorazepam, or levetiracetam, with slightly more use of levetiracetam for NCS than NCSE. CONCLUSIONS: Continuous EEG monitoring (cEEG) is commonly employed in critically illpatients to detect NCS and NCSE. However, there is substantial variability in current practice related to cEEG indications and duration and to management of NCS and NCSE. The fact that such variability exists in the management of this common clinical problem suggests that further prospective study is needed. Multiple points of uncertainty are identified that require investigation.
Authors: Jan Claassen; Lawrence J Hirsch; Jennifer A Frontera; Andres Fernandez; Michael Schmidt; Gregory Kapinos; John Wittman; E Sander Connolly; Ronald G Emerson; Stephan A Mayer Journal: Neurocrit Care Date: 2006 Impact factor: 3.210
Authors: Stacey K H Tay; Lawrence J Hirsch; Linda Leary; Nathalie Jette; John Wittman; Cigdem I Akman Journal: Epilepsia Date: 2006-09 Impact factor: 5.864
Authors: R J DeLorenzo; E J Waterhouse; A R Towne; J G Boggs; D Ko; G A DeLorenzo; A Brown; L Garnett Journal: Epilepsia Date: 1998-08 Impact factor: 5.864
Authors: Nicholas S Abend; Katherine L Wagenman; Taylor P Blake; Maria T Schultheis; Jerilynn Radcliffe; Robert A Berg; Alexis A Topjian; Dennis J Dlugos Journal: Epilepsy Behav Date: 2015-04-20 Impact factor: 2.937
Authors: Jan Claassen; Fabio S Taccone; Peter Horn; Martin Holtkamp; Nino Stocchetti; Mauro Oddo Journal: Intensive Care Med Date: 2013-05-08 Impact factor: 17.440
Authors: Franck Amyot; David B Arciniegas; Michael P Brazaitis; Kenneth C Curley; Ramon Diaz-Arrastia; Amir Gandjbakhche; Peter Herscovitch; Sidney R Hinds; Geoffrey T Manley; Anthony Pacifico; Alexander Razumovsky; Jason Riley; Wanda Salzer; Robert Shih; James G Smirniotopoulos; Derek Stocker Journal: J Neurotrauma Date: 2015-09-30 Impact factor: 5.269
Authors: Jonathan E Kurz; Samuel M Poloyac; Nicholas S Abend; Anthony Fabio; Michael J Bell; Mark S Wainwright Journal: Pediatr Crit Care Med Date: 2016-07 Impact factor: 3.624
Authors: Andrei Irimia; S-Y Matthew Goh; Carinna M Torgerson; Nathan R Stein; Micah C Chambers; Paul M Vespa; John D Van Horn Journal: Clin Neurol Neurosurg Date: 2013-08-12 Impact factor: 1.876
Authors: France W Fung; Marin Jacobwitz; Lisa Vala; Darshana Parikh; Maureen Donnelly; Rui Xiao; Alexis A Topjian; Nicholas S Abend Journal: Epilepsia Date: 2019-09-20 Impact factor: 5.864